Corticobasal degeneration (CBD) is a progressive neurological disorder. It is associated with atrophy of the cerebral cortex and the basal ganglia.
Corticobasal degeneration (CBD) generally occurs in patients age 45 to 70, with women affected more often than men. The combined loss of brain tissue in all these areas causes the symptoms. The initial symptoms often include stiff, shaky, slow and clumsy movements in either the arms or legs. Other early symptoms may include difficulty walking and balancing , short-term memory problems, difficulty controlling the muscles of the face and mouth.
Progressive difficulty speaking or articulating as well as difficulty comprehending language. Some of the symptoms, such as poor coordination and rigidity, are similar to those found in Parkinson's disease. Symptoms include parkinsonism such as poor coordination, akinesia (an absence of movements), rigidity (a resistance to imposed movement), and disequilibrium (impaired balance); and limb dystonia. Corticobasal degeneration usually progresses slowly over the course of 6 to 8 years. Death is generally caused by pneumonia or other complications of severe debility such as sepsis or pulmonary embolism.
Corticobasal degeneration is uncommon. There is no handling accessible to decelerate the class of corticobasal degeneration. Antiparkinsonian drugs do not develop any substantial or continuous advance. Clonazepam may assist the myoclonus. Occupational, physical, and address therapy may assist in managing impairment. Physical therapy may assist to preserve a scope of movement in tight joints, in twist helping to forbid pain and suffer mobility. Occupational therapy may be helpful in providing and developing useful adaptive equipment. Speech therapy may better articulation and book. Clonazepam may assist the myoclonus.
